KELOWNA, Canada – Tryp Therapeutics Inc., a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is pleased to announce that the first patient has been dosed in a Phase 2a clinical trial being conducted by the University of...
treatment News
Researchers at Tulane University, in collaboration with Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, have received a five-year $7.07 million grant from the National Institutes of Health (NIH) for continued development of detection kits for Lassa viral hemorrhagic fever, a serious disease spread by contact...
BOSTON, Mass. – GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. “Before this study, there...
PARIS — Two landmark clinical trials reported today at the Union meeting showed that an oral antibiotic taken for six months once-daily substantially reduced the risk of developing drug-resistant TB. The antibiotic levofloxacin safely reduced the risk of multidrug-resistant (MDR) tuberculosis (TB) disease in children by 56%, researchers from the...
Bochum, Germany – A research team from the Department of Medical and Molecular Virology at Ruhr University Bochum monitored and treated two patients with chronic hepatitis E with a combination of sofosbuvir and ribavirin after they had not previously responded to ribavirin alone. “In both cases, the combination therapy was...
Stockholm, Sweden – There does not appear to be any profound differences between so-called exposure-based CBT and traditional CBT in the treatment of fibromyalgia, according to a study led by researchers at Karolinska Institutet. Both forms of treatment produced a significant reduction in symptoms in people affected by the disease....
ORLANDO — Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are...
CARLSBAD, Calif. — Tyra Biosciences, Inc. a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it has initiated the SURF201 Phase 1 study of TYRA-200 and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300....
CARLSBAD, Calif. — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation to TYRA-300, an oral...
MINNEAPOLIS/ST. PAUL — Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder that affects children and adults, and can lead to kidney failure. New findings from a team led by the University of Minnesota Medical School show patients with FSGS who were treated with the medication sparsentan experienced improved kidney function—making...